Garza Salazar DP, Ocampo-Candiani J

Language: Spanish
References: 28
Page: 127-133
PDF size: 171.84 Kb.

ABSTRACT

Radiation Dermatitis is an increasing disorder due to the growing amount of patients requiring this treatment. In the majority of cases the skin effects of radiation are transient and minimal, but severe adverse effects can appear in a chronic or acute fashion. The grade of severity determines the choice of therapy; treatment options are: topical steroids, pentoxifiline, celecoxib, dexpanthenol and others without a proven clear benefit. Recently an Epidermal Growth Factor Receptor inhibitor (EGFR) has been approved as a therapeutic option for chemotherapy resistant non-small cells lung carcinoma (e.g. cetuximab). This drug improves cell sensitivity to radiation. The use of cetuximab in patients receiving radiation increases therapeutic effectiveness. Side effects such as case reports of radiodermatitis with this combination have been published, but its incidence and severity remains to be proven, so further studies are required.

REFERENCES

1. FitzGerald T, Bishop M, Tillman G, Aronowitz J, Pieters R, Balducci S et al. Radiation therapy toxicity to the skin. Dermatol Clin 2008; 26: 161-72.

2. Stone H, Coleman N, Anscher M, McBride W. Effects of radiation on normal tissue: consequences and mechanism. Lancet Oncol 2003; 4: 529-36.

3. Hymes S, Strom E, Fife C. Radiation dermatitis: Clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006; 54: 28-46.

4. Stone M, Robson K, LeBiot E. Subacute radiation dermatitis from fluoroscopy during coronary artery stenting: Evidence for cytotoxic lymphocyte mediated apoptosis. J Am Acad Dermatol 1998; 38: 336-6.

5. Kawakami T, Saito R, Miyazaki S. Chronic radiodermatitis following repeated percutaneous transluminal coronary angioplasty. Br J Dermatol 1999; 141: 150-3.

6. Moriyasu S, Yamamoto K, Kureyama N, Okamura K, Ikeda T, YAmatodani A. Involvement of Histamine Released From Mast Cells in Acute Radiation Dermatitis in Mice. J Pharmacol 2007; 104: 187-190.

7. Lichter M, Karagas M, Mott L, Spencer S, Stukel T, Greenberg E. Therapeutic Ionizing Radiation and the Incidence of Basal cell carcinoma and Squamous Cell Carcinoma. Arch Dermatol 2000; 136: 1007-11.

8. Ekmekci P, Bostanci S, Anadolu R, Erdem C, Gürgey E. Multiple Basal Cell Carcinoma Developed After Radiation Therapy for Tinea capitis: A case report. Dermatol Surg 2001; 27: 667-9.

9. Kim JH, Krivda SJ. Lichen planus confined to a radiation therapy site. J Am Acad Dermatol 2002; 46: 604-5.

10. Wickline MM. Prevention and Treatment of Acute Radiation Dermatitis: A Literature Review. Oncology Nursing forum 2004; 31: 237-44.

11. Schmuth M, Wimer MA, Hofer S, Sztankay A, Weinlich G, Linder D et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol 2002; 146: 983-91.

12. Pommier P, Gomez F, Sunyach MP, Carrie C, Montbarbon X. Phase III randomized trial of Calendula Officinalis Compared With Trolamine for the Prevention of Acute Dermatitis During Irradiation for Breast Cancer. J Clin Oncol 2004; 22: 1447-53.

13. Lanigan S, Joannides T. Pulsed dye laser treatment of telangiectasia after radiotherapy for carcinoma of the breast. Br J Dermatol 2003; 148: 77-9.

14. Escudero A, Nagore E, Sevila A, Sanmartin O, Botella R, Guillen C. Chronic X-ray dermatitis treated by topical 5-aminolaevulinic acid-photodynamic therapy. Br J Dermatol 2002; 147: 385-410.

15. Vergara G, Vargas-Machuca I, Pastor MA, Fariña M, Martín L, Requena L. Localization of Sweet’s syndrome in radiation-induced locus minoris resistentae. J Am Acad Dermatol 2003; 49: 907-9.

16. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother and Oncol 2001; 59: 237-45.

17. Yeo W, Johnson P. Radiation-Recall Skin Disorders Associated With the Use of Antineoplastic Drugs. Am J Clin Dermatol 2000; 1: 113-6.

18. Rueda RA, Valencia IC, Covelli C, Escobar C, Alzate A, Saldarriaga B. Eosinophilic, Polymorphic, and Pruritic Eruption Associated With Radiotherapy. Arch Dermatol 1999; 135: 804-10.

19. Del Pozo-Losada J, García-Silva J, Fonseca- Capdevila E. Fenómenos de recuerdo en dermatología. Piel 2007; 8: 115-20.

20. Blick S, Scott L. Cetuximab, A review of its use in squamous Cell Carcinoma of the Head and Neck and Metastatic Colorectal Cancer. Drugs 2007; 67: 2585-607.

21. Bernier J, Bonner J, Vermorken J, Bensadoun R, Dummer R, Giralt J et al. Consensus Guidelines for the Management of Radiation Dermatitis and Coexisting acne-like rash in Patients receiving radiotherapy plus EGFR Inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19: 142-9.

22. Agero A, Dusza S, Benvenuto-Andrade C, Busam K, Myskowski P, Halpern A. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657- 70.

23. Karamouzis M, Grandis J, Argiris A. TherapiesDirected Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas. JAMA 2007; 298: 70-82.

24. Bonner J, Harari P, Giralt J, Azarnia N, Shin D, Cohen R et al. Radiotherapy plus Cetuximab for Squamous Cell Carcinoma of the Head and Neck. N Engl J Med 2006; 354: 567-78.

25. Budach W, Bölke E, Homey B. Severe Cutaneous Reaction during Radiation Therapy with Concurrent Cetuximab. N Engl J Med 2007; 357: 514-5.

26. Bölke E, Gerber PA, Lammering G, Peiper M,Müller-Homey A, Pape H, et al. Development and management of severe cutaneous side effects in head-and- neck Cancer Patients during Concurrent Radiotherapy and Cetuximab. Strahlenther Onkol 2008; 184: 105- 10.

27. Roé E, Garcia M, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients. J Am Acad Dermatol 2006; 55: 429-37.

28. Berger B, Bel ka C. Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol 2008; 3: 5.